BAT Targets 30% Margin on Modern Nicotine by 2030
British American Tobacco said its New Category division—which includes nicotine pouches—will hit at least 30% contribution margin by decade's end, with revenue growing mid-teens annually.
British American Tobacco told investors it expects its New Category business—nicotine pouches, vapes, heated tobacco—to reach at least 30% contribution margin by 2030, with revenue growing at a mid-teens rate through the end of the decade.
The targets came during BAT's Capital Markets Day, where the company laid out its long-term financial outlook for the non-combustible portfolio that now includes VELO, the world's second-largest pouch brand.
What the Numbers Mean
Contribution margin measures revenue minus direct costs—essentially how much profit each dollar of New Category sales generates before corporate overhead. Hitting 30% would put BAT's modern nicotine division on par with profitability benchmarks in consumer packaged goods, a sign the company believes it can scale pouches and vapes without the margin drag that plagued early e-cigarette ventures.
Mid-teens revenue growth—call it 14-16% annually—implies BAT expects the category to roughly triple in size by 2030 if sustained from current levels. That pace would outstrip the single-digit decline in combustible cigarette revenue most analysts forecast for the same period.
VELO's Role
VELO is BAT's primary pouch play and the revenue engine behind much of the New Category forecast. The brand holds double-digit market share in the U.S., trails only ZYN domestically, and leads in several European markets. BAT has not broken out pouch-specific margin or growth figures, but VELO's scale—particularly in high-margin markets like Scandinavia—positions it as a core driver of the 2030 targets.
The margin goal also suggests BAT expects to reduce per-unit costs as pouch production scales and retail distribution becomes more efficient. Early pouch entrants often subsidized retailer margins and promotional pricing to build shelf space; a 30% margin implies those investments will taper.
What's Next
BAT's 2030 outlook depends on regulatory stability in key markets. The U.S. FDA has yet to authorize VELO through the premarket tobacco application process, and flavor restrictions in the EU could compress revenue growth if enacted broadly. The company has not detailed contingency scenarios if either risk materializes.
The targets also assume BAT can defend VELO's share against ZYN and a growing roster of regional challengers, many of which are undercutting on price to gain distribution.
SOURCES
Tobacco Reporter: BAT Hosts Capital Markets Day